Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EVAGELOS COSKINAS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1437382314
CMS profile
201763
Location
RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$497.65

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $497.65 10

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Teva Pharmaceuticals USA, Inc. $163.26 4
LivaNova USA, Inc. $124.93 1
E.R. Squibb & Sons, L.L.C. $118.79 1
Alkermes, Inc. $42.09 2
Indivior Inc. $27.61 1
Neurocrine Biosciences, Inc. $20.97 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EVAGELOS COSKINAS

NPI 1437382314 · CMS profile ID 201763

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437382314?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $497.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $118.7912/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101849410 CMS
Teva Pharmaceuticals USA, Inc. $126.2510/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646295 CMS
Teva Pharmaceuticals USA, Inc. $8.2808/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646291 CMS
Indivior Inc. $27.6105/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144526262 CMS
Teva Pharmaceuticals USA, Inc. $9.1504/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646265 CMS
Alkermes, Inc. $20.4804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120483926 CMS
Neurocrine Biosciences, Inc. $20.9704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150854746 CMS
Teva Pharmaceuticals USA, Inc. $19.5803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151646243 CMS
Alkermes, Inc. $21.6103/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120483924 CMS
LivaNova USA, Inc. $124.9303/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152799123 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $92.48 5
PY2020 $28.27 1
PY2021 $85.12 1
PY2022 $87.50 1
PY2023 $75.07 3
PY2024 $497.65 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,435,713.44 192
PY2024 Principal investigator $1,112,891.48 274
PY2023 Principal investigator $145,338.68 81
PY2021 Principal investigator $14,588.05 4
PY2020 Principal investigator $129,452.46 74
PY2019 Principal investigator $432,130.59 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

192 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,200.00 12/19/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine No dispute reported 06/30/2026 1235998080
Principal investigator 1 BioXcel Therapeutics, Inc. $3,650.00 12/09/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698342
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/05/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242368761
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 12/05/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242368763
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 12/05/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242368765
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,897.00 11/21/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine No dispute reported 06/30/2026 1235998074
Principal investigator 1 BioXcel Therapeutics, Inc. $756.68 11/17/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698326
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242366017
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242366019
Principal investigator 1 BioXcel Therapeutics, Inc. $476.55 11/04/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698310
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365049
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365051
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365053
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365055
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365057
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365059
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242365061
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363527
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363529
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363531
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363533
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363535
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363537
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363539
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363541
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363543
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 10/10/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242363545
Principal investigator 1 BioXcel Therapeutics, Inc. $1,513.36 10/06/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698270
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242359118
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 09/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242359120
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 09/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242359122
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,000.00 09/18/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder No dispute reported 06/30/2026 1235998078
Principal investigator 1 BioXcel Therapeutics, Inc. $28,687.11 09/15/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698254
Principal investigator 1 BioXcel Therapeutics, Inc. $4,734.93 09/15/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698256
Principal investigator 1 ABBVIE INC. $1,500.00 09/09/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202510370
Principal investigator 1 ABBVIE INC. $650.00 09/04/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202510106
Principal investigator 1 ABBVIE INC. $33,984.50 08/27/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202506217
Principal investigator 1 ABBVIE INC. $20,147.80 08/27/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202506219
Principal investigator 1 ABBVIE INC. $17,784.20 08/27/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202506221
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,356.63 08/26/2025 Non-covered Recipient Entity
Precise Research Center
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235994571
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $203.92 08/26/2025 Non-covered Recipient Entity
Precise Research Center
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235994573
Principal investigator 1 Axsome Therapeutics, Inc. $2,119.44 08/13/2025 Non-covered Recipient Entity
Clinical Innovations, Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917430
Principal investigator 1 BioXcel Therapeutics, Inc. $300.00 08/11/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698218
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,650.05 07/31/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049853
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,817.92 07/31/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049855
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $544.72 07/28/2025 Non-covered Recipient Entity
Guardian Angel Research Center
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235997031
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,393.37 07/28/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235998072
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,471.67 07/28/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder No dispute reported 06/30/2026 1235998076
Principal investigator 1 Axsome Therapeutics, Inc. $2,180.00 07/23/2025 Non-covered Recipient Entity
Clinical Innovations, Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917428
Principal investigator 1 ABBVIE INC. $115,783.11 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202498468
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353725
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353727
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353733
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353735
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353737
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353739
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353741
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353743
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353745
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/16/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242353747
Principal investigator 1 BioXcel Therapeutics, Inc. $2,974.54 07/08/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698190
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242352883
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242352885
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 07/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242352887
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,767.21 06/25/2025 Non-covered Recipient Entity
The Start Center For Cancer Care
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1235993057
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 06/24/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049847
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,746.00 06/24/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049849
Principal investigator 1 BioXcel Therapeutics, Inc. $8,090.94 06/19/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698078
Principal investigator 1 BioXcel Therapeutics, Inc. $25,641.97 06/19/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698080
Principal investigator 1 Axsome Therapeutics, Inc. $427.95 06/13/2025 Non-covered Recipient Entity
Clinical Innovations, Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917424
Principal investigator 1 Axsome Therapeutics, Inc. $7,834.14 06/13/2025 Non-covered Recipient Entity
Clinical Innovations, Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917426
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350288
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350290
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350294
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350296
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350298
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350300
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350302
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350304
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350306
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350366
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350768
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350770
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350772
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350774
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350776
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350778
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 06/13/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242350780
Principal investigator 1 ABBVIE INC. $5,397.60 06/04/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC DBA CITRIALS
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202490157
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $55,500.00 05/28/2025 Non-covered Recipient Entity
Citrials
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia No dispute reported 06/30/2026 1235998144
Principal investigator 1 BioXcel Therapeutics, Inc. $120.00 05/20/2025 Non-covered Recipient Entity
CITRIALS
BXCL501401 No dispute reported 06/30/2026 1228698022
Principal investigator 1 Axsome Therapeutics, Inc. $89.62 05/16/2025 Non-covered Recipient Entity
Clinical Innovations, Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917422
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $104,092.69 05/14/2025 Non-covered Recipient Entity
Clinical Innovations, Incorporated
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235998070
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346619
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346621
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346623
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346625
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346627
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346629
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346647
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346649
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346651
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346653
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346655
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346657
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346677
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346679
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346681
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346683
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346685
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346687
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346689
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346721
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242346723
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242347180
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 05/07/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242347182
Principal investigator 1 ABBVIE INC. $900.00 04/28/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC DBA CITRIALS
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202479793
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343249
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343253
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343255
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343257
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343259
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343363
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343365
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343367
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343369
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343371
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343373
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343375
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343377
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343379
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343381
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343383
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343385
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343387
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343389
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343391
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343393
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343395
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343397
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343399
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343401
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343403
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/11/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242343405
Principal investigator 1 ABBVIE INC. $2,500.00 04/02/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202468576
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,039.00 04/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049839
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 04/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049841
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 04/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049843
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 04/01/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049845
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336911
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336913
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336915
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336917
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336919
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336921
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336923
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336997
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242336999
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,897.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337001
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,897.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337003
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337219
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337221
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337223
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337225
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337227
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337285
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337287
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337289
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337291
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337293
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337295
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337297
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6.93 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337859
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 03/12/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242337861
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16,968.00 03/03/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242334592
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,381.40 02/05/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049837
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,256,444.00 01/22/2025 Non-covered Recipient Entity
Cenexel Cit
A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants with DSM-5 Schizophrenia No dispute reported 06/30/2026 1235998302
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328717
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328719
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20,000.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328753
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328759
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328761
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328763
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328765
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328767
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328769
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242328771
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 01/22/2025 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1242329741
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $112,583.49 01/06/2025 Non-covered Recipient Entity
Cenexel Cit
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235998306
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $59,250.00 01/03/2025 Non-covered Recipient Entity
Cenexel Cit
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235998304